VIA Pharmaceuticals (VIAP) Stock Analysis & Winston Score

VIA Pharmaceuticals is a small pharmaceutical company focused on developing drugs to treat cardiovascular diseases, particularly conditions related to abnormal heart rhythms and related complications. The company works on experimental medicines that have not yet reached widespread commercial use, meaning it is still in the research and development stage rather than selling products at scale.

The company generates little to no revenue at this stage, which is typical for early-phase drug developers that spend most of their money on clinical trials and research before any product is approved. VIA Pharmaceuticals operates primarily in the United States and has a very small market presence. Because it has no approved products generating consistent sales, its main risk is running out of cash before successfully advancing a drug through clinical trials and regulatory approval — a challenge that affects most small biotech and pharma companies at this stage of development.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+43.2% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

1.7%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~0 months

$84,001 cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Cash watch

VIA Pharmaceuticals has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

—

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial